A randomised determination of the effect of fluvastatin and atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial

Wenaweser, Peter; Eshtehardi, Parham; Abrecht, Linda; Zwahlen, Marcel; Schmidlin, Kurt; Windecker, Stephan; Meier, Bernhard; Haeberli, Andre; Hess, Otto M (2010). A randomised determination of the effect of fluvastatin and atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial. Thrombosis and haemostasis, 104(3), pp. 554-562. Stuttgart: Schattauer 10.1160/TH09-11-0765

[img] Text
Wenaweser ThrombHaemost 2010.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (298kB) | Request a copy

Drug-drug interaction between statins metabolised by cytochrome P450 3A4 and clopidogrel have been claimed to attenuate the inhibitory effect of clopidogrel. However, published data regarding this drug-drug interaction are controversial. We aimed to determine the effect of fluvastatin and atorvastatin on the inhibitory effect of dual antiplatelet therapy with acetylsalicylic acid (ASA) and clopidogrel. One hundred one patients with symptomatic stable coronary artery disease undergoing percutaneous coronary intervention and drug-eluting stent implantation were enrolled in this prospective randomised study. After an interval of two weeks under dual antiplatelet therapy with ASA and clopidogrel, without any lipid-lowering drug, 87 patients were randomised to receive a treatment with either fluvastatin 80 mg daily or atorvastatin 40 mg daily in addition to the dual antiplatelet therapy for one month. Platelet aggregation was assessed using light transmission aggregometry and whole blood impedance platelet aggregometry prior to randomisation and after one month of receiving assigned statin and dual antiplatelet treatment. Platelet function assessment after one month of statin and dual antiplatelet therapy did not show a significant change in platelet aggregation from 1st to 2nd assessment for either statin group. There was also no difference between atorvastatin and fluvastatin treatment arms. In conclusion, neither atorvastatin 40 mg daily nor fluvastatin 80 mg daily administered in combination with standard dual antiplatelet therapy following coronary drug-eluting stent implantation significantly interfere with the antiaggregatory effect of ASA and clopidogrel.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine

UniBE Contributor:

Wenaweser, Peter Martin; Abrecht, Linda; Zwahlen, Marcel; Schmidlin, Kurt; Windecker, Stephan; Meier, Bernhard and Hess, Otto

ISSN:

0340-6245

Publisher:

Schattauer

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:10

Last Modified:

11 Sep 2017 21:09

Publisher DOI:

10.1160/TH09-11-0765

PubMed ID:

20664903

Web of Science ID:

000281969900017

BORIS DOI:

10.7892/boris.1579

URI:

https://boris.unibe.ch/id/eprint/1579 (FactScience: 203356)

Actions (login required)

Edit item Edit item
Provide Feedback